Skip to main content
Clinical Trials/ACTRN12619000831189
ACTRN12619000831189
Completed
未知

Respiratory Rate in patients with Respiratory Failure in response to Nasal High Flow Therapy delivered via a single sealed nostril

Fisher & Paykel Healthcare0 sites28 target enrollmentJune 7, 2019

Overview

Phase
未知
Intervention
Not specified
Conditions
Respiratory Failure
Sponsor
Fisher & Paykel Healthcare
Enrollment
28
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 7, 2019
End Date
January 18, 2021
Last Updated
4 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\.Patient is receiving NHF therapy with Optiflow\+ nasal interface
  • 2\.Nasal High Flow rate \>/\= 30 L·min\-1
  • 3\.FiO2 is between 0\.21 and 0\.80

Exclusion Criteria

  • 1\.Less than 18 years’ old
  • 2\.Hemodynamic instability
  • 3\.Respiratory failure secondary to cardiac failure
  • 4\.Neurological or neuromuscular pathologies and/or known phrenic nerve dysfunction
  • 5\.Clinician deems patient will not be stable for the duration of the study

Outcomes

Primary Outcomes

Not specified

Similar Trials